Skip to content Skip to footer
Subscribe Now
NEWS

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front 

Shots :Coherus signs an agreement with Sandoz to divest its ophthalmology franchise which includes a lead asset Cimerli (ranibizumab-eqrn) along with its supporting commercial infrastructure As per the terms of the agreement, Coherus will receive an all-cash consideration of $170M as up-front payment along with an additional amount for Cimerli product inventory &…
January 4, 2024

Read more

Insights+ Key Biosimilars Events of September 2023
INSIGHTS+

Insights+ Key Biosimilars Events of September 2023

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patientsDuring the month of September, Sandoz entered into a development and commercialization agreement…
October 4, 2023

Read more

Insights+ Key Biosimilars Events of August 2023
INSIGHTS+

Insights+ Key Biosimilars Events of August 2023

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patientsDuring the month of August, Sandoz’ Tyruko (biosimilar, natalizumab) received the US FDA’s…
September 6, 2023

Read more

Insights+ Key Biosimilars Events of July 2023
INSIGHTS+

Insights+ Key Biosimilars Events of July 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of July, Samsung Bioepis reported P-III equivalence study…
August 4, 2023

Read more

Insights+ Key Biosimilars Events of June 2023
INSIGHTS+

Insights+ Key Biosimilars Events of June 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of June, Samsung Bioepis presented results of SB12…
July 5, 2023

Read more

Insights+ Key Biosimilars Events of May 2023
INSIGHTS+

Insights+ Key Biosimilars Events of May 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of May, Celltrion’s Yuflyma (biosimilar, adalimumab) received the…
June 7, 2023

Read more

Insights+ Key Biosimilars Events of April 2023
INSIGHTS+

Insights+ Key Biosimilars Events of April 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of April, Sandoz’s Hyrimoz (biosimilar, adalimumab) received EC’s…
May 3, 2023

Read more

Insights+ Key Biosimilars Events of March 2023
INSIGHTS+

Insights+ Key Biosimilars Events of March 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of March, Biogen launched Byooviz (biosimilar, ranibizumab) for…
April 5, 2023

Read more

Insights+ Key Biosimilars Events of February 2023
INSIGHTS+

Insights+ Key Biosimilars Events of February 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of February, Alvotech entered into a commercialization agreement…
March 1, 2023

Read more

Load more